Tri-Methyl-Histone H3 (Lys36) Antibody

What is Tri-Methyl-Histone H3 (Lys36) and its role in chromatin regulation?

Histone H3 is one of the four core components of the nucleosome, which forms the basic unit of chromatin. The nucleosome consists of 147 base pairs of DNA wrapped around an octamer of histone proteins (two each of H2A, H2B, H3, and H4). Trimethylation at lysine 36 of histone H3 (H3K36me3) is a critical post-translational modification that serves as a marker of transcribed genes. This modification is established by specific methyltransferases, including Set2 in yeast and NSD1 in mammals . H3K36me3 is predominantly associated with transcriptional elongation by RNA polymerase II holoenzyme, making it an important epigenetic mark for actively transcribed regions of the genome .

Unlike some histone modifications that repress gene expression, H3K36me3 typically weakens the binding between histone tails and DNA, making the genetic material more accessible to transcription factor proteins and the RNA polymerase machinery . This characteristic positions H3K36me3 as a crucial regulator in the complex landscape of epigenetic control mechanisms governing gene expression.

How does H3K36me3 differ from other histone H3 lysine 36 methylation states?

H3K36 can exist in three different methylation states: mono-methylated (H3K36me1), di-methylated (H3K36me2), and tri-methylated (H3K36me3). Each state has distinct biological implications and genomic distributions:

H3K36me3 is specifically recognized by Tri-Methyl-Histone H3 (Lys36) antibodies that have been validated for high specificity to this trimethylated form. The specificity of these antibodies is crucial for distinguishing between the different methylation states of H3K36 . While H3K36me2 has been shown to lead to transcriptional elongation and acts as a marker of transcribed genes , H3K36me3 has more specific roles in processes like alternative splicing regulation and prevention of cryptic transcription.

What are the validated applications for Tri-Methyl-Histone H3 (Lys36) Antibody?

Tri-Methyl-Histone H3 (Lys36) Antibody has been validated for numerous research applications, each with specific recommended dilutions and protocols:

These applications enable researchers to investigate H3K36me3 at multiple levels, from protein detection to genome-wide distribution analysis. The antibody has demonstrated reactivity with human, mouse, and rat samples, with predicted cross-reactivity to other species including horse, sheep, and rabbit based on sequence conservation .

What sample preparation methods optimize detection of H3K36me3?

Optimal sample preparation is crucial for successful detection of H3K36me3 across different applications:

For Western Blot:

• Extract protocols should include histone acid extraction or specialized nuclear extraction methods

• Use 25 μg of protein per lane for optimal detection

• Blocking with 3% nonfat dry milk in TBST is recommended

• Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10,000 dilution

For Immunohistochemistry:

• High-pressure antigen retrieval with 0.01 M citrate buffer (pH 6.0) is critical prior to IHC staining

• Paraffin-embedded sections should be processed at recommended dilutions of 1:50 - 1:200

• Signal detection systems should be optimized for nuclear staining patterns

For ChIP and ChIP-Seq:

• Crosslinking conditions must be carefully controlled

• Sonication parameters should be optimized to generate 200-500 bp DNA fragments

• Use validated positive control primers targeting known H3K36me3-enriched regions

• Human Positive Control Primer Set ACTB-1 and Human Negative Control Primer Set 1 have been validated for qPCR following ChIP with this antibody

Proper sample storage is essential for maintaining antibody efficacy. Store at -20°C, avoid repeated freeze/thaw cycles by aliquoting into single-use fractions, and keep all reagents on ice when not in storage .

How can researchers validate the specificity of their Tri-Methyl-Histone H3 (Lys36) Antibody results?

Validating antibody specificity is critical for ensuring reliable results. The following methods are recommended:

• Peptide competition assays: Compare antibody binding with and without pre-incubation with the specific methylated peptide. A significant reduction in signal after peptide competition confirms specificity.

• Dot blot analysis: Test antibody against a panel of differently modified histone peptides. The dot blot data from search result shows high specificity for H3K36me3 with minimal cross-reactivity to other histone modifications.

• Use of positive and negative controls:

  • HeLa nuclear extract serves as a reliable positive control for H3K36me3 detection

  • Include samples where H3K36me3 is known to be absent or reduced

  • For ChIP experiments, use validated control primer sets:

    • Human Positive Control Primer Set ACTB-1 (Cat. No. 71003)

    • Human Negative Control Primer Set 1 (Cat. No. 71001)

    • Mouse Negative Control Primer Set 1 (Cat. No. 71011)

• Knockdown validation: Use cells with genetic knockdown of H3K36 methyltransferases (e.g., SETD2) to confirm signal specificity.

• Western blot molecular weight verification: Confirm that the detected band appears at approximately 17 kDa, consistent with histone H3 .

What are the most common technical issues with H3K36me3 antibodies and how can they be addressed?

In cases of Western blot issues, the recommended exposure time is approximately 10 seconds when using ECL Basic Kit for detection . For ChIP applications, using highly validated antibodies with consistent lot performance is essential for reproducible results.

How can Tri-Methyl-Histone H3 (Lys36) Antibody be used to study chromatin dynamics during development and disease?

Tri-Methyl-Histone H3 (Lys36) Antibody enables sophisticated investigations into dynamic chromatin states across various biological contexts:

• Developmental studies:

  • Track H3K36me3 distribution changes during cellular differentiation

  • Compare embryonic stem cells with differentiated lineages to identify developmentally regulated genes

  • Investigate tissue-specific patterns using immunohistochemistry on tissue sections (dilution 1:50-1:200)

• Disease modeling:

  • Examine changes in H3K36me3 distribution in cancer cell lines versus normal cells

  • Investigate neurodegenerative conditions where epigenetic dysregulation is implicated

  • Study metabolic disorders where transcriptional regulation may be altered

• Integration with multi-omics approaches:

  • Combine ChIP-Seq (dilution 1:20-1:100) with RNA-Seq to correlate H3K36me3 patterns with gene expression

  • Integrate with DNA methylation profiling to understand epigenetic crosstalk

  • Perform sequential ChIP (Re-ChIP) to identify genomic regions with co-occurring modifications

• Drug response studies:

  • Monitor H3K36me3 changes following treatment with epigenetic modifiers

  • Assess impact of targeted therapies on global chromatin structure

  • Identify potential biomarkers for therapeutic response

The antibody has been validated in western blot analysis of various cell lines , enabling comparative studies across different cellular models. Immunohistochemistry analysis of paraffin-embedded human lung tissue has also been successfully performed (dilution 1:100) , demonstrating its utility in studying tissue-specific epigenetic patterns.

What are the latest methodological advances for studying H3K36me3 in single cells or limited sample materials?

Recent technological developments have expanded the capability to study H3K36me3 in scenarios with limited biological material:

• CUT&RUN and CUT&Tag technologies:

  • These methods require significantly less input material than traditional ChIP

  • The Tri-Methyl-Histone H3 (Lys36) antibody has been validated for both CUT&RUN and CUT&Tag applications

  • Provides improved signal-to-noise ratio compared to conventional ChIP

• Low-input ChIP adaptations:

  • Micro-ChIP protocols allow H3K36me3 profiling from as few as 10,000 cells

  • Carrier-based methods improve immunoprecipitation efficiency with limited samples

  • Optimized buffers and handling procedures minimize material loss

• Single-cell epigenomic approaches:

  • Integration with single-cell technologies to map H3K36me3 at individual cell resolution

  • Requires specialized library preparation and highly sensitive detection methods

  • Enables correlation of epigenetic heterogeneity with cellular phenotypes

• Signal amplification techniques:

  • For immunofluorescence/immunocytochemistry applications (1:50-1:200 dilution)

  • Tyramide signal amplification can enhance detection sensitivity

  • Multiplex imaging with other histone modifications for comprehensive epigenetic profiling

When working with limited samples, careful optimization of antibody concentration is essential. The recommended dilution ranges (1:500-1:1,000 for Western Blot, 1:50-1:200 for IHC) should be precisely titrated for each experimental system to maximize signal while minimizing background .

What controls should be included in experiments using Tri-Methyl-Histone H3 (Lys36) Antibody?

Proper experimental controls are critical for generating reliable and interpretable data when using Tri-Methyl-Histone H3 (Lys36) Antibody:

• Positive controls:

  • HeLa nuclear extract has been validated as a positive control for H3K36me3 detection

  • Known H3K36me3-enriched gene bodies (e.g., actively transcribed housekeeping genes)

  • For human samples, the ACTB-1 primer set has been validated for qPCR following ChIP

• Negative controls:

  • Isotype control antibodies: Rabbit IgG (specific products recommended in search result )

  • Genomic regions known to lack H3K36me3 enrichment

  • For human samples, Human Negative Control Primer Set 1 has been validated for qPCR

  • For mouse samples, Mouse Negative Control Primer Set 1 has been validated

• Technical controls:

  • Input sample (pre-immunoprecipitation chromatin) for ChIP experiments

  • No primary antibody controls for immunostaining applications

  • Blocking peptide competition to demonstrate specificity

  • Dot blot analysis against a panel of modified peptides

• Biological validation:

  • SETD2 knockdown/knockout cells (main H3K36 trimethylase in mammals)

  • Treatment with methyl-transferase inhibitors to reduce global H3K36me3 levels

  • Comparison across cell types with known differences in H3K36me3 distribution

In ChIP-Seq experiments, include spike-in controls (e.g., Drosophila chromatin with species-specific antibody) to enable normalization across samples with potentially global changes in H3K36me3 levels.

How can researchers design experiments to investigate the relationship between H3K36me3 and transcriptional regulation?

To effectively study the relationship between H3K36me3 and gene expression, consider these experimental design strategies:

• Integrated genomic approaches:

  • Perform parallel H3K36me3 ChIP-Seq (antibody dilution 1:20-1:100) and RNA-Seq on matched samples

  • Include additional histone marks (H3K4me3, H3K27ac) to distinguish active promoters and enhancers

  • Analyze the correlation between H3K36me3 enrichment patterns and transcript levels

• Perturbation studies:

  • Manipulate H3K36me3 levels through SETD2 knockdown/knockout

  • Assess the impact on transcriptional output genome-wide

  • Examine effects on RNA polymerase II occupancy and elongation rate

• Temporal dynamics:

  • Design time-course experiments during cellular differentiation or response to stimuli

  • Monitor changes in H3K36me3 distribution and corresponding gene expression

  • Determine whether H3K36me3 changes precede or follow transcriptional changes

• Mechanistic investigations:

  • Study the recruitment of H3K36me3 readers (proteins that bind this modification)

  • Examine the relationship between H3K36me3 and RNA splicing patterns

  • Investigate the interplay between H3K36me3 and other epigenetic marks

• Single-gene focused studies:

  • Perform ChIP-qPCR along the length of model genes

  • Create detailed maps of H3K36me3 distribution relative to transcriptional elements

  • Correlate with RNA polymerase II occupancy and transcriptional output

When designing these experiments, careful consideration should be given to antibody dilutions for different applications. For ChIP and ChIP-Seq, the recommended dilution range is 1:20-1:100 , while for Western blotting, 1:500-1:1,000 is typically optimal .